Period | Baseline screening | Follow-up period | |||
---|---|---|---|---|---|
Interview | 1 | 2 | 3 | 4 | 5 |
Days | -7~-1 | 1 | 28 ± 5 | 56 ± 5 | 84 ± 5 |
Informed consent | √ | ||||
Baseline characteristics | √ | ||||
Physical exams/urinalysis/ Kidney and liver functions | √ | ||||
H1Abc | √ | √ | |||
Inclusion exclusion criteria review | √ | ||||
Random allocation | √ | ||||
Digital intervention1 | √ | √ | √ | √ | |
Conventional therapy | √ | √ | √ | √ | |
Incentives2 | √ | √ | √ | ||
SMBG testing rate3 | √ | √ | √ | ||
Weight4 | √ | √ | √ | ||
Scale evaluation5 | √ | √ | √ | √ | |
Medical expenses6 | √ | √ | √ | √ | |
Adverse events evaluation | √ | √ | √ | √ |